120 related articles for article (PubMed ID: 10231516)
1. Uterine leiomyomas with T-cell infiltration associated with GnRH agonist goserelin.
Laforga JB; Aranda FI
Histopathology; 1999 May; 34(5):471-2. PubMed ID: 10231516
[No Abstract] [Full Text] [Related]
2. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis.
McClean G; McCluggage WG
Int J Surg Pathol; 2003 Oct; 11(4):339-44. PubMed ID: 14615835
[TBL] [Abstract][Full Text] [Related]
3. Massive lymphocytic infiltration of uterine leiomyomas associated with GnRH agonist treatment.
Bardsley V; Cooper P; Peat DS
Histopathology; 1998 Jul; 33(1):80-2. PubMed ID: 9726054
[TBL] [Abstract][Full Text] [Related]
4. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
5. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
6. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
Crow J; Gardner RL; McSweeney G; Shaw RW
Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
[TBL] [Abstract][Full Text] [Related]
7. Progesterone: a critical role in the pathogenesis of uterine myomas.
Rein MS; Barbieri RL; Friedman AJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):14-8. PubMed ID: 7847524
[TBL] [Abstract][Full Text] [Related]
8. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
Colgan TJ; Pendergast S; LeBlanc M
Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
[TBL] [Abstract][Full Text] [Related]
9. [The role of the immune factor in the pathogenesis of uterine myoma].
Zudikova SI
Akush Ginekol (Mosk); 1988 May; (5):11-3. PubMed ID: 3263058
[No Abstract] [Full Text] [Related]
10. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
11. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
12. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
13. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
15. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
16. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
17. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
[TBL] [Abstract][Full Text] [Related]
18. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
19. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
